EMA Recommends Granting a Marketing Authorisation for Senaparib By Ogkologos - October 15, 2026 36 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the maintenance treatment of advanced epithelial ovarian, Fallopian tube and primary peritoneal cancer Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Daraxonrasib for Metastatic Pancreatic Adenocarcinoma Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL Meet the first recipient of the ESMO Artificial Intelligence Fellowship MOST POPULAR Poorer Survival in Obese Colorectal Cancer Patients Possibly Linked to Lower... July 2, 2021 Disguising Cancer as an Infection Helps the Immune System Eliminate Tumors July 22, 2022 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... September 2, 2025 Mutational Patterns Drive Metastatic Aggressiveness of Appendiceal Adenocarcinomas December 21, 2022 Load more HOT NEWS Overall Breast Cancer Incidence Down Since 1999, Rates Increase for Women... Adjuvant mRNA-4157 Plus Pembrolizumab Prolongs RFS versus Pembrolizumab Alone in Patients... PD1 and LAG3 Inhibition Plus Chemoradiotherapy in the Neoadjuvant Setting for... 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive...
